Tirzepatide tops semaglutide for patient weight loss, study finds Grace Halsey , Richard Payerchin Key Takeaways Tirzepatide showed a 47% greater weight reduction than semaglutide in the SURMOUNT-5 trial, with significant secondary endpoint superiority
We prioritize Omadas progress above team or individual
The use of semaglutide is not yet approved in children under 12 years of age, and geriatric use in sensitive populations is relatively lacking in safety data [9]
in Cell Metabolism note that SIRT1 activation improves mitochondrial efficiency and promotes a shift toward lipid utilization for energy, which can be especially beneficial in endurance and fat-loss settings (Price et al., Cell Metabolism )
Thats why results tend to build steadily over time
If you are pregnant, planning to become pregnant, or breastfeeding, who should avoid taking retatrutide includes you